Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
PRNewswire - December 16, 2005
CAMBRIDGE, Mass., Dec. 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) presented positive results today from a study evaluating the safety, tolerability and antiviral activity of the investigational HIV-1 protease inhibitor (PI), brecanavir* (formerly known as GW640385 or VX-385)(1). These data were presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in Washington DC. Interim findings following 24 weeks of dosing demonstrated potent antiviral activity for brecanavir in both PI-sensitive and PI-resistant HIV-infected adults.
"These results support the ongoing development program for brecanavir, which is anticipated to enter Phase III development in 2006," said Lynn Marks, MD, Senior Vice President of the Infectious Disease Medicines Development Centre at GSK. "If approved, brecanavir may be useful in treating patients infected with strains of HIV that have become resistant to multiple protease inhibitors, and its clinical advancement underscores GSK's commitment to developing new anti-HIV drugs."
Clinical Data on Brecanavir
Brecanavir is an HIV protease inhibitor in Phase IIb clinical development. Brecanavir has received fast track designation from the U.S. Food and Drug Administration and is being developed by GSK as part of a collaboration with Vertex Pharmaceuticals.
Data presented were from a planned, 24-week analysis of an open-label study (HPR10006) of 48 weeks' duration evaluating the safety, tolerability, antiviral activity and pharmacokinetics of ritonavir-boosted brecanavir. Thirty-one HIV-1 infected adults received 300mg of brecanavir twice-daily boosted with 100mg of ritonavir in combination with two nucleoside reverse transcriptase inhibitors based on patient medical history and viral genotype.
Out of 31 patients, 81 percent had plasma HIV-1 RNA below the level of detection of standard assays (<400 copies/mL of blood) at Week 24 (based on an intent-to-treat, missing or discontinuation equals failure analysis), and 77 percent had viral load below the level of detection of ultrasensitive assays (<50 copies/mL). Patients with PI-sensitive and highly PI-resistant virus had similar response rates. Improvements in immunologic status were observed, with a median increase in CD4+ cell count of 84 cells/mm3.
"These early data are encouraging and support the further development of brecanavir in clinical trials in both antiretroviral treatment-naive and experienced patients," commented lead investigator Douglas Ward, MD, FACP of the Dupont Circle Physicians Group. "Because many HIV-infected patients undergoing treatment develop viral resistance to those medicines already available, a critical need for new antiretrovirals remains."
A safety assessment showed that brecanavir was well-tolerated with few Grade 2-4 drug-related adverse events and no serious adverse events. Most adverse events were reported as mild and did not require treatment modification or discontinuation. Clinically relevant changes in laboratory assessments were also infrequent.
About HIV Protease
Once inside a human immune cell, HIV uses enzymes within that cell to make copies of itself. Protease is one such enzyme involved in HIV replication. HIV protease inhibitors block the HIV protease enzyme, yielding copies of HIV that cannot infect new cells.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is principally focused on viral diseases, inflammation, autoimmune diseases and cancer.
Vertex Safe Harbor Statement
This press release may contain forward-looking statements, including that (i) it is anticipated brecanavir will enter Phase III development in 2006; and (ii) brecanavir may be useful in treating patients infected with resistant HIV strains. While management makes its best efforts to be accurate in making forward-looking statements, such statements are subject to risks and uncertainties that could cause the actual results of studies to vary materially, including those risks and uncertainties listed under Risk Factors in Vertex's Form 10-K filed with the Securities and Exchange Commission on March 16, 2005.
Vertex's press releases are available at http://www.vrtx.com.
Vertex Contacts:
Lynne H. Brum, VP, Corporate Communications and Financial Planning, (617) 444-6614
Michael Partridge, Director, Corporate Communications, (617) 444-6108
Lora Pike, Manager, Investor Relations, (617) 444-6755
Zachry Barber, Specialist, Media Relations, (617) 444-6470
(1) D. Ward, et al. Preliminary Antiviral Activity and Safety of 640385/Ritonavir in HIV-infected Patients (Study HPR10006); an 8-Week Interim Analysis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, Dec 2005.
*The generic name is USAN approved only.
SOURCE Vertex Pharmaceuticals Incorporated
Web Site: http://www.vrtx.com
051216
PR051225
Copyright © 2005 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .